Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
$28.51
-0.4%
$26.81
$17.93
$30.46
$16.73B0.88334,640 shs270,122 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$49.30
+0.0%
$43.72
$20.14
$52.92
$6.11B1.372.13 million shs1.67 million shs
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$59.86
+7.9%
$45.09
$13.47
$72.98
$13.40B2.0921.24 million shs41.92 million shs
Natera, Inc. stock logo
NTRA
Natera
$168.25
+1.8%
$154.56
$92.14
$183.00
$22.97B1.741.41 million shs1.15 million shs
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
0.00%+0.24%-0.54%+18.26%+38.70%
Guardant Health, Inc. stock logo
GH
Guardant Health
0.00%+2.56%+21.19%+14.90%+63.16%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
0.00%-1.97%-14.15%+59.54%+132.97%
Natera, Inc. stock logo
NTRA
Natera
0.00%+0.96%+8.36%+10.78%+50.04%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
3.5738 of 5 stars
1.05.02.50.03.10.04.4
Guardant Health, Inc. stock logo
GH
Guardant Health
3.7564 of 5 stars
2.53.00.04.32.02.50.6
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.62 of 5 stars
2.03.00.00.02.63.31.9
Natera, Inc. stock logo
NTRA
Natera
1.1488 of 5 stars
1.52.00.00.03.02.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
2.00
Hold$27.80-2.90% Downside
Guardant Health, Inc. stock logo
GH
Guardant Health
3.00
Buy$53.769.13% Upside
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
2.08
Hold$38.00-36.17% Downside
Natera, Inc. stock logo
NTRA
Natera
3.00
Buy$184.6310.79% Upside

Current Analyst Ratings Breakdown

Latest NTRA, FMS, HIMS, and GH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/13/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$60.00 ➝ $65.00
6/11/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$40.00
6/4/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$61.00 ➝ $65.00
5/15/2025
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingUnderweight ➝ Underweight
5/15/2025
Natera, Inc. stock logo
NTRA
Natera
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$205.00 ➝ $210.00
5/12/2025
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$25.00 ➝ $30.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$211.00 ➝ $218.00
5/9/2025
Natera, Inc. stock logo
NTRA
Natera
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$160.00 ➝ $190.00
5/7/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/6/2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMixed ➝ Mixed
5/6/2025
Guardant Health, Inc. stock logo
GH
Guardant Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$50.00 ➝ $60.00
(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
$19.49B0.86$5.77 per share4.96$27.34 per share1.05
Guardant Health, Inc. stock logo
GH
Guardant Health
$774.00M7.89N/AN/A$1.34 per share36.76
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$1.78B7.47N/AN/A$1.61 per share36.98
Natera, Inc. stock logo
NTRA
Natera
$1.83B12.43N/AN/A$6.37 per share26.16
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
$540.07M$1.1223.6614.910.763.43%6.04%2.69%7/29/2025 (Estimated)
Guardant Health, Inc. stock logo
GH
Guardant Health
-$479.45M-$3.39N/AN/AN/A-59.05%-19,157.20%-25.96%8/6/2025 (Estimated)
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
-$23.55M$0.69135.00114.49N/A8.19%10.97%8.29%8/4/2025 (Estimated)
Natera, Inc. stock logo
NTRA
Natera
-$434.80M-$1.47N/AN/AN/A-14.01%-26.23%-14.27%8/14/2025 (Estimated)

Latest NTRA, FMS, HIMS, and GH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Natera, Inc. stock logo
NTRA
Natera
-$0.59-$0.50+$0.09-$0.50$446.68 million$501.83 million
5/6/2025Q1 2025
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
$0.43$0.44+$0.01$0.26$4.71 billion$5.54 billion
5/5/2025Q1 2025
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
$0.12$0.20+$0.08$0.20$535.21 million$586.01 million
4/30/2025Q1 2025
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.57-$0.49+$0.08-$0.77$189.91 million$203.47 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
$0.571.99%N/A50.89%N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/AN/AN/AN/AN/A
Natera, Inc. stock logo
NTRA
Natera
N/AN/AN/AN/AN/A

Latest NTRA, FMS, HIMS, and GH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/9/2025
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
annual$0.78711.9%5/23/20255/23/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
0.42
1.37
1.02
Guardant Health, Inc. stock logo
GH
Guardant Health
N/A
6.22
5.85
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
N/A
2.14
1.82
Natera, Inc. stock logo
NTRA
Natera
0.33
4.39
4.23

Institutional Ownership

CompanyInstitutional Ownership
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
8.37%
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
63.52%
Natera, Inc. stock logo
NTRA
Natera
99.90%

Insider Ownership

CompanyInsider Ownership
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
6.10%
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
13.71%
Natera, Inc. stock logo
NTRA
Natera
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Fresenius Medical Care AG stock logo
FMS
Fresenius Medical Care
123,200586.83 millionN/AOptionable
Guardant Health, Inc. stock logo
GH
Guardant Health
1,790123.89 million116.76 millionNot Optionable
Hims & Hers Health, Inc. stock logo
HIMS
Hims & Hers Health
650223.83 million179.79 millionOptionable
Natera, Inc. stock logo
NTRA
Natera
3,020136.55 million121.99 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Fresenius Medical Care stock logo

Fresenius Medical Care NYSE:FMS

$28.51 -0.10 (-0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$28.48 -0.02 (-0.08%)
As of 05:26 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.

Guardant Health stock logo

Guardant Health NASDAQ:GH

$49.30 +0.01 (+0.02%)
Closing price 04:00 PM Eastern
Extended Trading
$48.94 -0.36 (-0.74%)
As of 04:13 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health stock logo

Hims & Hers Health NYSE:HIMS

$59.86 +4.38 (+7.89%)
Closing price 03:59 PM Eastern
Extended Trading
$60.10 +0.24 (+0.41%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Natera stock logo

Natera NASDAQ:NTRA

$168.25 +2.91 (+1.76%)
Closing price 04:00 PM Eastern
Extended Trading
$168.24 -0.01 (-0.01%)
As of 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.